MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2019 International Congress

    Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study

    R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, Y. Thongchuam, T. Boonmongkol, P. Garcia Ruiz (Bangkok, Thailand)

    Objective: To evaluate the long-term efficacy of APO in PD patients treated at two specialist centres in Spain and Thailand, and to determine the reasons…
  • 2019 International Congress

    Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease

    C. Olanow, F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, R. Kleiman, D. Blum, B. Navia (New York, NY, USA)

    Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…
  • 2018 International Congress

    Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial

    S. Factor, S. Isaacson, K. Sciarappa, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Atlanta, GA, USA)

    Objective: To evaluate the efficacy of APL-130277 (APL) in a double-blind, placebo-controlled trial. Background: OFF episodes are a common, disabling complication of Parkinson’s disease (PD)…
  • 2018 International Congress

    Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial

    R. Pahwa, R. Hauser, M. Worden, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Kansas City, KS, USA)

    Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…
  • 2018 International Congress

    Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection

    S. Isaacson (Boca Raton, FL, USA)

    Objective: We evaluated a subset of patients who were enrolled in the AMIMPAKT trial of sc apomorphine injection to treat morning akinesia (see reference) who…
  • 2018 International Congress

    Patient’s Choice of Device-Based Treatments in Parkinson’s Disease

    M. Kuzu Kumcu, S. Tezcan Aydemir, Ç. Ulukan, B. Bakırarar, C. Akbostancı (Ankara, Turkey)

    Objective: Deep brain stimulation of subtalamic nucleus (STN-DBS), subcutaneous apomorphine infusion (APO) and levodopa-carbidopa intestinal gel infusion (DUO) is routinely used in patients with advanced…
  • 2018 International Congress

    Atypical Response to Apomorphine in a Patient with Multiple System Atrophy

    S. Ozben, F. Genc, F. Tuter Yilmaz, A. Erdal, N. Atis (Antalya, Turkey)

    Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…
  • 2017 International Congress

    Alternative Apomorphine Challenge Test

    J.C. Martinez Castrillo, A. Alonso Canovas, C. Estevez Fraga, G. Sanchez Diez, I. Avilés Olmos, J. Lopez Sendon, P. Garcia Ruiz, L. Vela Desojo (Madrid, Spain)

    Objective: To propose a new apomorphine challenge test Background: In the standard apomorphine challenge test, the appropriate dose of apomorphine is established by incremental dosing…
  • 2017 International Congress

    The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments

    R. Borgemeester, T. van Laar (Groningen, Netherlands)

    Objective: To review the outcome of continuous apomorphine infusion (CAI) in advanced Parkinson’s disease (PD) patients at the rehabilitation unit of the Parkinson Expertise Center…
  • 2017 International Congress

    Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration

    J.-F. Houvenaghel, S. Drapier, J. Duprez, D. Drapier, M. Vérin (Rennes, France)

    Objective: The aim of the present study was to investigate the influence of apomorphine pump in Parkinson’s disease (PD) on motor and nonmotor symptoms, including…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley